Literature DB >> 3262088

Specific parasitism of purified vaginal epithelial cells by Trichomonas vaginalis.

J F Alderete1, P Demeś, A Gombosova, M Valent, M Fabusová, A Jánoska, J Stefanovic, R Arroyo.   

Abstract

Human vaginal epithelial cells (VECs) from vaginal swabs obtained from normal women or from patients with trichomoniasis were purified, and VEC parasitism by Trichomonas vaginalis was examined. Trichomonads bound equally well to live or dead VECs, and up to 20% of VECs were parasitized. Trichomonal cytadherence of human VECs was time, temperature, and pH dependent. Saturation binding levels of live trichomonads to VECs gave approximately 2 organisms adherent to parasitized VEC. No differences in cytadherence levels were detected by different isolates to VECs from the same patient compared with adherence to VECs from normal individuals. Trypsinized, live T. vaginalis organisms failed to recognize VECs. A ligand assay identified four adhesin candidates, and only organisms without a prominent immunogen on the surface (negative phenotype) cytadhered to VECs and synthesized the adhesins, confirming the results of a recently published report by us on adherence to HeLa cell monolayers (J. F. Alderete and G. E. Garza, Infect. Immun. 56:28-33, 1988). These data show the ability of T. vaginalis to parasitize human vaginal epithelial cells in a specific receptor-ligand manner.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262088      PMCID: PMC259611          DOI: 10.1128/iai.56.10.2558-2562.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Phenotypic variation and diversity among Trichomonas vaginalis isolates and correlation of phenotype with trichomonal virulence determinants.

Authors:  J F Alderete; L Kasmala; E Metcalfe; G E Garza
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

2.  Pathogenicity of fresh isolates of Trichomonas vaginalis: "the mouse assay" versus clinical and pathologic findings.

Authors:  B M Honigberg; M C Livingston; J K Frost
Journal:  Acta Cytol       Date:  1966 Sep-Oct       Impact factor: 2.319

3.  Selective acquisition of plasma proteins by Trichomonas vaginalis and human lipoproteins as a growth requirement for this species.

Authors:  K M Peterson; J F Alderete
Journal:  Mol Biochem Parasitol       Date:  1984-05       Impact factor: 1.759

4.  Evaluation of an enzyme-linked immunosorbent assay for the detection of antibody to Trichomonas vaginalis in sera and vaginal secretions.

Authors:  D A Street; D Taylor-Robinson; J P Ackers; N F Hanna; A McMillan
Journal:  Br J Vener Dis       Date:  1982-10

5.  Host plasma proteins on the surface of pathogenic Trichomonas vaginalis.

Authors:  K M Peterson; J F Alderete
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

6.  Pathogenic Trichomonas vaginalis cytotoxicity to cell culture monolayers.

Authors:  J F Alderete; E Pearlman
Journal:  Br J Vener Dis       Date:  1984-04

7.  Contact-dependent cytopathogenic mechanisms of Trichomonas vaginalis.

Authors:  J N Krieger; J I Ravdin; M F Rein
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

8.  Morphological studies of the cytotoxicity of Trichomonas vaginalis to normal human vaginal epithelial cells in vitro.

Authors:  S E Rasmussen; M H Nielsen; I Lind; J M Rhodes
Journal:  Genitourin Med       Date:  1986-08

9.  Iron uptake and increased intracellular enzyme activity follow host lactoferrin binding by Trichomonas vaginalis receptors.

Authors:  K M Peterson; J F Alderete
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

10.  Trichomonas vaginalis is dependent on uptake and degradation of human low density lipoproteins.

Authors:  K M Peterson; J F Alderete
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  16 in total

1.  Vaginal antibody of patients with trichomoniasis is to a prominent surface immunogen of Trichomonas vaginalis.

Authors:  J F Alderete; E Newton; C Dennis; J Engbring; K A Neale
Journal:  Genitourin Med       Date:  1991-06

2.  Dot-immunobinding assay with monoclonal antibody for detection of Trichomonas vaginalis in clinical specimens.

Authors:  A Gombosová; M Valent
Journal:  Genitourin Med       Date:  1990-12

3.  Relatedness of structures of a major immunogen in Trichomonas vaginalis isolates.

Authors:  J F Alderete; K A Neale
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

4.  Trichomonas vaginalis surface proteinase activity is necessary for parasite adherence to epithelial cells.

Authors:  R Arroyo; J F Alderete
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

5.  Host and tissue specificity of Trichomonas vaginalis is not mediated by its known adhesion proteins.

Authors:  M F Addis; P Rappelli; P L Fiori
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

6.  Analysis of the proteinases of representative Trichomonas vaginalis isolates.

Authors:  K A Neale; J F Alderete
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

7.  Adherence of Tritrichomonas foetus to bovine vaginal epithelial cells.

Authors:  L B Corbeil; J L Hodgson; D W Jones; R R Corbeil; P R Widders; L R Stephens
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

8.  Association of production of cell-detaching factor with the clinical presentation of Trichomonas vaginalis.

Authors:  G E Garber; L T Lemchuk-Favel
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

9.  The vagina of women infected with Trichomonas vaginalis has numerous proteinases and antibody to trichomonad proteinases.

Authors:  J F Alderete; E Newton; C Dennis; K A Neale
Journal:  Genitourin Med       Date:  1991-12

10.  Innate immunity in the vagina (part I): estradiol inhibits HBD2 and elafin secretion by human vaginal epithelial cells.

Authors:  Mickey V Patel; John V Fahey; Richard M Rossoll; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2013-02-08       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.